larg line guidanc street estim result due feb
perform organ sale growth clear level
target quarter year think stock
reflect oper momentum along investor enthusiasm pipelin
anoth quarter highlight organ sale growth around
expect organ revenu growth would duplic
success perform constant currenc sale growth
organ sale growth reach currenc expect neg impact sale
bp top-lin forecast compar street estim
close match manag target quarter importantli
attribut modest differ consensu sale number simpli conserv
model us note face second-easiest sale growth comp fiscal
stack basi howev sequenti comp setup similar
factor along increment tailwind play fuel in-line-or-bett
revenu result turn satisfi investor support stock
also think street earn forecast achiev
ep forecast match street estim fall midpoint
guidanc sale project weve remain conserv
margin assumpt model flat om perform rel prior-
year quarter line street handl om manag call
slight improv om off-set currenc headwind year expect
bp increas om conserv bp shi guidanc anticip
neg currenc impact ep think compani like
exceed incom statement project believ sale growth
reson investor solid ep show would help track bit closer
lrp ep growth target despit tax-chang headwind face year
second-half sale momentum continu thank new product launch
fiscal continu expect organ revenu growth approxim
foreign currenc neg impact bp follow result
compani rais organ sale growth guidanc three four divis
cvg growth forecast vs previous mitg project
vs previous rtg target vs previous contrast
manag lower diabet organ sale growth estim result
low single-digit growth prior assumpt diabet would grow low
end guidanc rang revenu growth accompani oper
margin expans roughli bp help mdt on-going enterpris excel
initi lastli manag increas ep guidanc rang
result revis ep guidanc rang includ
impact currenc vs previous reflect growth midpoint
remind mdt lrp five pillar organ revenu growth underli
annual oper margin expans bp adjust ep growth
assum modest currenc volatil convers calendar
minimum return sharehold given prospect anoth
quarter organ sale growth help recent product launch mdt setup
head print attract view
pleas see page report import disclosur
outperform rate driven optimist outlook
sustain mid-single-digit top-lin growth trajectori combin mdt/cov
entiti combin cost synergi tax rate improv expect
new meet/exce goal grow adjust ep faster
revenu expect pipelin growth driver like becom focu investor
product contribut meaning first full year commerci
view new continu top-tier top- bottom-lin growth
perform medic devic space
launch surgic robot platform
on-going rollout product
resolut onyx
maintain de market share
us
stabil us spine
strong adopt tavr portfolio
us
return growth spine franchis
out-year top-lin growth acceler
market share loss
continu deterior spine
weak adopt trend new product
diversifi medic technolog servic solut compani presenc
countri combin entiti covidien
merger new oper four segment cardiac vascular group
minim invas therapi group diabet restor therapi group cardiac
vascular group segment manufactur market device-bas medic therapi
cardiac rhythm heart failur crhf coronari structur heart aortic
peripher vascular mitg focus advanc gener surgic technolog
diabet segment manufactur market device-bas medic therapi diabet
restor therapi group segment manufactur market device-bas medic
therapi spine neuromodul surgic technolog
rais target
new price target blend price-to-earnings ev/ebitda multipl
respect adjust fiscal forecast multipl close current
mean multipl large-cap peer view appropri remain
bullish mdt pipelin prospect continu believ long-rang plan
target achiev reiter outperform rate
thomson one cowen compani compani file
mm exclud rhythm heart structur monitor invas constant currenc revenu organ constant currenc revenu good interest expens share quartercowen estimatesconsensusprior year cowen
thomson one cowen compani compani file
consensu guidanc sale estim organ guidanc organ neg fximpact bpscowen ep estim report reportedguid neg fximpact sale growth round level manag target quarterli guidanc expect perform well-receiv investor like continu focu mdt robust pipelin prospect faster revenu growth oper margin cowen estim flat year year guidanc slight improv oper margin off-set currenc headwind compar expect full-year improvementheadwind lsd top-lin growthcontinu sale pressur high-margin dcb franchisechina tariff fx tailwind enterpris excel program progressimprov sg leveragefull-year earningscowen includ fximpact modest oper margin expans cowen forecast full-year improv bpstax rate increas associ tax reformtailwind share repurchasefisc year end april year end april y/i ex-fx impact cowen
thomson one cowen compani compani file
cvg setup similar street estim guidancecowen sale estim cc ccguidanc growthin back half fiscal cvg anniversari challeng dcb lvad multipl new product launchestoprovid growth divis also face second-easiest sale growth comp year make setup favor rel conserv model headwindsaort peripher venou continu albeit eas dcb pressur due paclitaxel safeti concernstailwind second-easiest cvg sale growth comp fiscal structur heart strength tavr within structur heart on-going us low-risk tavr launchsolid initi traction evolutpro continu negoti new us tavr center follow recent ncdcardiac rhythm heart failur continu solid growth afeasiest year-over-year comp fiscal fall share gain micra drive pace resultsstrength diagnost continu uptak reveal linqaf growth help arcticfrontcryoballoonanniversari lvad share loss market contractionaort peripher venou taa strength behind valiant navion growth on-going dcb launch japancontinu adopt venasealclosur system venousu launch pactfor av fistula fiscal year end april year end april y/i y/i ex-fx cowen
thomson one cowen compani compani file
mitg setup similar street estim guidancecowen sale estim ccguidanc growthth mitg unit lap second-toughest quarterli comparison howev divis experienc consider momentum growth year toughest comp benefit new product launch balanc think guidanc attain headwindssecond-toughest quarterli sale comp mitg innov second-toughest growth comp year bp sequenti basi toughest comprespiratori gi renal lap strength busi combin sale growth surgic innov continu momentum advanc surgic via deeper convers open procedur misadvanc stapl experienc strength eea circular stapler tri-stapleadvanc benefit ligasurevessel seal nano-co ligasur exact dissector l-hook laparascop sealer/divid energi platformrespiratori gi renal solid perform across patient monitor gi solut respiratorypati monitor driven nellcorpuls oximetri microstreamcapnographi bi consumablesgi solut seen double-digit growth reflux care respiratori above-market strength come puritan bennett ventil mcgrath video laryngoscopesin renal solut strength continuefisc year end april year end april therapi y/i y/i ex-fx cowen
cowen compani
rtg setup similar street estim guidancecowen sale estim cc growthrtg face easiest comp year last quarter divis post impress organ growth thank spineand brain therapi view guidanc conserv particularli given signific step-down year-over-year comp sequenti basi headwindsspin second-toughest comp brain therapi featur second-hardest global sale comp year lap double-digit growth intern businessestailwind easiest rtg sale growth comp fiscal fall enabl technolog surgic synergi strategi continu gain traction new product like infin oct system stratospher along prestig lp disc provid benefit core spinebrain therapi strength neurovascular neurosurgeryneurovascular continu adopt hemorrhag flow divers ischem stroke solitair riptid react cathet neurosurgeri momentum navig mazorx stealth edit initi uptak mida therapi signific eas growth comp rel intern busi benefit dynamicspecialti therapi continu momentum ent power instrument nerv monitor navig pelvic health interstim fiscal year end april year end april y/i y/i ex-fx cowen
thomson one cowen compani compani file
diabet setup similar street estim guidancecowen sale estim ccguidanc flat slightli downmanag expect low-single-digit diabet sale growth fiscal compani await new product launch intern diabet franchis repres total diabet revenu base expect carri load off-set competit pressur believ compani deliv in-lin better sale show insulin manag continu pressur competit insulin pump emerg pressur competit tailwind continu strong growth intern emerg marketsadvanc insulin manag instal base grew user exit drive higher consum sale cgm revenueintern franchis sustain solid growth trajectori on-going launch select countriesemerg continu adopt guardian connect cgmthe guardian sensor launch emea region user year end april year end april y/i y/i ex-fx cowen
figur pipelin overview near-term product mileston
cowen compani compani file
pipelin overview near-term product milestonesminim franc reimbursementpercept pc db passiv sens approvallinq approvalev- us pivot first implantsnext-gen crt-d approvalinterstim micro approvalmidasrex launchminim germani reimbursementin pact av access dataguardian sensor non-adjunct approvaltmvr transfemor fih/u feasibl trial startminim extend wear infus set ce marksoft-tissu robot initi launchfallwinterspringdiamond-af us pivot trial datamicra av fda approvalrdn symplic us pivot trial off-m datain pact av access fda approvaltavr evolut pro includ pro fda us pivot trial datamicra trial datanext-gen intelli fda approvalminim approvaldiamondtemp af eu launchtavr risk fda approvalcvg-risk tavrarcticfront advanc cryoballoonmicra vrvenas closur systemevolut pro dcb av access micra avrev linq temp rf europ ev-sympl renal denervationpuls field ablationintrepid mitral valvemitgsignia power staplerligasur vessel sealingpillcaminvo technologiesriptid aspir react cathetetersolitair xtitan spinedtm intellisinterstim micro surescan leadspercept pc dbsnext-gen nim nerv monitoringpipelin vantag europ closed-loop dbsnext-gen spine-en technologydiabeteszeu cgm sensorsynergi cgm sensorbeyondsonicis platform updaterobotic-assist surgeri platformminim advanc hybrid closed-loop systemextend wear infus setpillcam geniusport hemodialysi systemperson closed-loop technologyhemorrhag stroke intrasaccular devicedriv growth nowminim us ou guardian connect stand-alone sensor us ou launch expect quarter cowen
thomson one cowen compani compani file
thomson one cowen compani compani file
medtron incom statement mm except per share y/i y/i cc good incom tax net dilut share y/i y/i cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial econom sensit
price pressur and/or weaken demand develop market econom and/or
polit uncertainti emerg market electrophysiolog clinic commun deem
st jude medic durata lead safe effect yale independ review infus
biolog cite cancer promot effect fluctuat foreign exchang rate
